Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Texas |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00033085 |
The purpose of this study is to assess the efficacy and safety of ondansetron to reduce cocaine use in subjects with cocaine dependence.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders Drug Administration Schedule |
Drug: Ondansetron |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | Double-Blind, Placebo-Controlled Trial of Ondansetron for the Treatment of Cocaine Dependence |
Estimated Enrollment: | 60 |
Study Start Date: | May 2001 |
Estimated Study Completion Date: | December 2002 |
Double-blind, placebo-controlled, 4-parallel group design to assess the efficacy and safety of 3 wide range doses of ondansetron to reduce cocaine use in subjects with cocaine dependence and to determine the optimal dose of ondansetron.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Male/Female, at least 18 yrs of age; DSM-4 diagnosis of cocaine dependence; seeking Treatment for cocaine dependence; have ability to understand, having understood and provide written consent; females of child bearing potential that use accepted method of birth control
Exclusion Criteria:
Additional criteria available during screening at the site.
United States, Texas | |
University of Texas Hlth Sci Ctr San Ant | |
San Antonio, Texas, United States, 78284 7828 |
Principal Investigator: | John Roache, Ph.D. | University of Texas |
Study ID Numbers: | NIDA-CTO-0005-1 |
Study First Received: | April 5, 2002 |
Last Updated: | July 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00033085 |
Health Authority: | United States: Food and Drug Administration; United States: Federal Government |
Cocaine-Related Disorders Mental Disorders Substance-Related Disorders Disorders of Environmental Origin |
Ondansetron Cocaine Serotonin |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Gastrointestinal Agents Central Nervous System Depressants Antiemetics Antipsychotic Agents Pharmacologic Actions |
Serotonin Antagonists Serotonin Agents Autonomic Agents Therapeutic Uses Antipruritics Anti-Anxiety Agents Peripheral Nervous System Agents Central Nervous System Agents Dermatologic Agents |